HEADLINES: High Price of Unproven, Hugely Expensive Alzheimer Drug Demonstrates Urgent Need for H.R. 3 and Medicare Negotiation
This week, the FDA approved Biogen’s unproven and hugely expensive Alzheimer's drug, Aducanumb, and experts…
protectourcareJune 9, 2021